Baird served as co-manager on this offering
AboutAssembly Biosciences, Inc. (“Assembly” or the “Company”) (NASDAQ-GS: ASMB) recently completed an underwritten public offering of 6,287,878 shares of its common stock at a price to the public of $16.50 per share. In addition, and in lieu of common stock, Assembly is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2,424,242 shares of common stock at a purchase price of $16.499 per pre-funded warrant. The aggregate gross proceeds to Assembly from the offering are expected to be approximately $143.7 million.
Assembly is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. Assembly Biosciences, Inc. is headquartered in Carmel, Indiana.
CONTACT US TO LEARN MORE
- December 2019
- Assembly Biosciences, Inc.
- Target Location
- North America